ECTS2016 Poster Presentations Cancer and bone: basic, translational and clinical (37 abstracts)
LIGHT promotes osteolytic bone metastases in NSCLC patients
Giacomina Brunetti 1 , Dimas Carolina Belisario 2 , Valentina Alliod 3 , Lucio Buffoni 3 , Silvia Colucci 1 , Maria Grano 1 , Riccardo Ferracini 4 & Ilaria Roato 2
1Department of Basic and Medical Sciences, Neurosciences and Sense Organs, Section of Human Anatomy and Histology, University of Bari, Bari, Italy; 2CeRMS, A.O. Città della Salute e della Scienza, Torino, Italy; 3Department of Medical Oncology, A.O. Città della Salute e della Scienza, Torino, Italy; 4C.T.O., A.O. Città della Salute e della Scienza, Torino, Italy.
LIGHT is a TNF superfamily member, expressed by activated T cells. It is involved in erosive bone disease, such as rheumatoid arthritis where it stimulates osteoclastogenesis. In multiple myeloma, LIGHT promotes osteolysis by increasing osteoclastogenesis and inhibiting osteoblastogenesis. We investigated whether LIGHT has a role in the osteolytic bone metastatic process induced by non small cell lung cancer (NSCLC), which is a tumor with a marked osteotropism. We analysed by flow citometry the expression of LIGHT on CD4 and CD8 T cells, CD14 monocytes, CD16 neutrophils from peripheral blood of patients and controls. CD8 had a low expression of LIGHT, whereas CD4 expressed it at high level, but without significant differences between the groups. Interestingly, we showed that LIGHT expression was significantly higher in monocytes from bone metastatic patients than non-bone metastatic ones. Since osteoclasts (OCs) originate from monocytes, we studied whether LIGHT interferes with the OC formation in vitro by plating PBMCs from NSCLC patients and healthy controls. PBMCs from patients with bone metastases differentiate into OCs without stimulating factors (M-CSF and RANKL), but when we add an anti-LIGHT monoclonal antibody (mAb), we detected a significant dose-dependent inhibition of osteoclastogenesis. For PBMCs of NSCLC patients without bone metastases and healthy controls, we induced osteoclastogenesis with M-CSF and RANKL, and when we add anti-LIGHT mAb, we again reported a significant decrease in OC formation, but only with the highest dose of the mAb, thus suggesting a synergic effect with RANKL. We also dosed LIGHT serum levels without detecting significant differences between patients and controls.
Thus our data demonstrated that the high expression of LIGHT sustains OC formation, suggesting a role of LIGHT in the bone metastatic process from NSCLC.
Article tools
My recent searches
My recently viewed abstracts
Authors
Bone Abstracts
ISSN 2052-1219 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more